We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , AbbVie Inc. (ABBV - Free Report) , TotalEnergies SE (TTE - Free Report) , Linde plc (LIN - Free Report) and AT&T Inc. (T - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Berkshire Hathaway, AbVie and TotalEnergies
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., AbbVie Inc., and TotalEnergies SE. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Berkshire Hathaway shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+1.1% vs. -3.3%). The company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions.
A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility. Continued insurance business growth fuels increase in float, drives earnings and generates maximum return on equity.
The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus. However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
AbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+27.6% vs. +15.8%). The Zacks analyst believes that the company has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta.
It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Skyrizi and Rinvoq are going strong, bolstered by approval in new indications. It has an impressive late-stage pipeline and several early/mid-stage candidates that have blockbuster potential.
Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic areas, enhancing its long-term growth potential. However, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica's sales. AbbVie's shares have outperformed the industry this year so far.
TotalEnergies shares have gained +44.3% over the past year against the Zacks Oil and Gas - Refining and Marketing industry's gain of +19.0%. The Zacks analyst believes that the company is gaining from new startups, increase in commodity prices, well-spread LNG assets and an expanding upstream portfolio that has exposure to fast-growing hydrocarbon producing regions.
TTE streamlines its portfolio through acquisitions, partnerships and divestitures. TTE is making regular investments to expand renewable operation and aims to achieve net-zero emission by 2050.
TTE has enough liquidity to meet debt obligations. However, TTE's profitability is likely to have been impacted by natural decline in the oil and natural gas fields. TTE remains exposed to acquisition-related risks as these assets contribute a sizable volume to production. TTE has operations in some politically-troubled regions and the ongoing Russia and Ukraine conflict might affect profitability.
Other noteworthy reports we are featuring today include Linde plc and AT&T Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T
For Immediate Release
Chicago, IL – June 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , AbbVie Inc. (ABBV - Free Report) , TotalEnergies SE (TTE - Free Report) , Linde plc (LIN - Free Report) and AT&T Inc. (T - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Berkshire Hathaway, AbVie and TotalEnergies
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., AbbVie Inc., and TotalEnergies SE. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Berkshire Hathaway shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+1.1% vs. -3.3%). The company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions.
A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility. Continued insurance business growth fuels increase in float, drives earnings and generates maximum return on equity.
The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus. However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
(You an read the full research report on Berkshire Hathaway here >>>)
AbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+27.6% vs. +15.8%). The Zacks analyst believes that the company has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta.
It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Skyrizi and Rinvoq are going strong, bolstered by approval in new indications. It has an impressive late-stage pipeline and several early/mid-stage candidates that have blockbuster potential.
Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic areas, enhancing its long-term growth potential. However, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica's sales. AbbVie's shares have outperformed the industry this year so far.
(You an read the full research report on AbbVie here >>>)
TotalEnergies shares have gained +44.3% over the past year against the Zacks Oil and Gas - Refining and Marketing industry's gain of +19.0%. The Zacks analyst believes that the company is gaining from new startups, increase in commodity prices, well-spread LNG assets and an expanding upstream portfolio that has exposure to fast-growing hydrocarbon producing regions.
TTE streamlines its portfolio through acquisitions, partnerships and divestitures. TTE is making regular investments to expand renewable operation and aims to achieve net-zero emission by 2050.
TTE has enough liquidity to meet debt obligations. However, TTE's profitability is likely to have been impacted by natural decline in the oil and natural gas fields. TTE remains exposed to acquisition-related risks as these assets contribute a sizable volume to production. TTE has operations in some politically-troubled regions and the ongoing Russia and Ukraine conflict might affect profitability.
(You an read the full research report on TotalEnergies here >>>)
Other noteworthy reports we are featuring today include Linde plc and AT&T Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.